相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
F. Castagnetti et al.
LEUKEMIA (2015)
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
L. Kalmanti et al.
LEUKEMIA (2015)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?
Mladen V. Tzvetkov et al.
BLOOD (2014)
Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
Anne T. Nies et al.
CLINICAL CANCER RESEARCH (2014)
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia
Athina Giannoudis et al.
BLOOD (2013)
Can specific OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
Herman Burger et al.
BLOOD (2013)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling
Matthias B. Wittwer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Transport Mechanisms and Their Pathology-Induced Regulation Govern Tyrosine Kinase Inhibitor Delivery in Rheumatoid Arthritis
Christian Schmidt-Lauber et al.
PLOS ONE (2012)
Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins
Tsuyoshi Minematsu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib
Deborah L. White et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Potent and Specific Inhibition of mMate1-Mediated Efflux of Type I Organic Cations in the Liver and Kidney by Pyrimethamine
Sumito Ito et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Chronic Myeloid Leukemia CD34+cells have reduced uptake of imatinib due to low OCT-1 Activity
J. R. Engler et al.
LEUKEMIA (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical pharmacokinetics of tyrosine kinase inhibitors
Nielka P. van Erp et al.
CANCER TREATMENT REVIEWS (2009)
Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function
Ying Chen et al.
PHARMACOGENOMICS JOURNAL (2009)
Organic cation transporters OCT1, 2, and 3 mediate high-affinity transport of the mutagenic vital dye ethidium in the kidney proximal tubule
Wing-Kee Lee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Interaction of imatinib with human organic ion carriers
Shuiying Hu et al.
CLINICAL CANCER RESEARCH (2008)
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells
Gerard Minuesa et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
Deborah L. White et al.
BLOOD (2007)
Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications
Hermann Koepsell et al.
PHARMACEUTICAL RESEARCH (2007)
Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H-2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates
K.-I. Umehara et al.
XENOBIOTICA (2007)
Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain
Anne Amphoux et al.
NEUROPHARMACOLOGY (2006)
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML
D White et al.
BLOOD (2005)
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2
WM Suhre et al.
MOLECULAR PHARMACOLOGY (2005)
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588
P le Coutre et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3
M Hayer-Zillgen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
分享论文
